The American Association for Cancer Research has called on Congress "to summarily reject" the Trump administration's 2026 ...

as well as in Canada. AZ estimates that around 1,000 patients in England alone will now miss out on treatment with Enhertu, and patient organisation Breast Cancer NOW described the outcome as a ...

but MSD (known as Merck & Co in the US and Canada) paid $20 million upfront to Alteogen, with up to $432 million in back-end milestones. Enhertu is fast becoming a major growth product for Daiichi ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

LONDON - AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company, Limited have announced that their drug Enhertu (trastuzumab deruxtecan) has shown a statistically significant improvement in ...

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09 trial, when used as a ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...